KLTO
Klotho Neurosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About KLTO
Klotho Neurosciences, Inc.
A company focused on developing new disease-improving technologies for the treatment of neurodegenerative diseases and age-related conditions
Life Science Tools and Services
03/16/2021
04/29/2022
NASDAQ Stock Exchange
3
12-31
Common stock
13576 Walnut Street, Suite A, Omaha, NE 68144
--
Klotho Neurosciences, Inc., was incorporated in Delaware on March 16, 2021. The company specializes in developing patented novel disease improvement technologies, including key developments in the treatment of neurodegenerative and age-related diseases. ANEW is developing cutting-edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer's and Parkinson's diseases, ALS and rare neurodegenerative diseases. Other assets include global rights to multiple platform technologies, including a melanocortin peptide library that has been proven to regulate hunger, food intake and weight loss, and ANEW's dry nanoparticle powder injection system called Nanoject, a patented medical device for the safe and painless self-injection of insulin, GLP-1 agonists, fertility drugs and many other drugs, vaccines and protein molecules.
Company Financials
EPS
KLTO has released its 2022 Q2 earnings. EPS was reported at -1.86, versus the expected 0.00, missing expectations. The chart below visualizes how KLTO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
